Exosome Treatment for Parkinson's - Bob скачать в хорошем качестве

Exosome Treatment for Parkinson's - Bob

Updated 4/1/2025: This Parkinson’s disease (PD) patient has had several exosome treatments beginning in May 2024.   1 year after treatment, he is significantly improved without sign of regression.  This apparent disease-modifying activity has not been previously seen after any PD treatment.   Chadwick Prodromos, MD, is a board-certified orthopaedic surgeon and regenerative medicine/stem cell expert. He earned his Bachelor’s degree from Princeton University, MD from Johns Hopkins Medical School, completed a surgical internship at the University of Chicago, a residency in orthopaedic surgery at Rush University, and a fellowship in orthopaedic surgery and sports medicine at Harvard Medical School - Mass Gen Hospital. He is the editor of the comprehensive textbook for orthopaedic surgeons on the ACL. He was an assistant professor of orthopaedic surgery at Rush University for 27 years before stepping back to focus on his 501c3 nonprofit, Research and Education Foundation for Regenerative Medicine (TheFoReM.org). He is the Medical Director of the Prodromos Stem Cell Institute (ThePSCI.com). The Prodromos Stem Cell Institute performs completely safe, world-leading mesenchymal stem cell and exosome treatment, treating a variety of difficult disorders, and has had great success with back/neck pain, autism, arthritis, auto-immune disorders, anti-aging, and more recently, Parkinson's disease and ALS. Prioritizing evidence and science, the PSCI is one of the only stem cell institutes worldwide that conducts research, regularly publishing in high-quality medical journals. Prodromos Stem Cell Institute: https://www.ThePSCI.com Illinois Sports Medicine: https://www.ISMOC.net Foundation for Regenerative Medicine: https://www.TheFoReM.org Connect with us online Follow Dr. Prodromos on Facebook:   / chadwickprodromosmd   Follow Dr. Prodromos on Instagram:   / chadprodromosmd   Follow Dr. Prodromos on LinkedIn:   / the-prodromos-stem-cell-institute